Opus Genetics vs Relay Therapeutics
Opus Genetics and Relay Therapeutics are similar in size: $14.2m and $15.4m of revenue in their latest fiscal years. Relay Therapeutics grew faster (53.4% against 29.1%). Opus Genetics kept more of each dollar of sales as profit: a net margin of -349.3% against -1800.6%. Relay Therapeutics carries less debt relative to equity (0.0% against 7.4%).
| Latest fiscal year | Opus GeneticsIRD, 2025 | Relay TherapeuticsRLAY, 2025 |
|---|---|---|
| Revenue | $14.2m | $15.4m |
| Revenue growth | 29.1% | 53.4% |
| Net income | −$49.6m | −$276m |
| Operating margin | -271.9% | -1971.6% |
| Net margin | -349.3% | -1800.6% |
| Return on equity | — | -41.1% |
| Free cash flow | −$35.3m | −$236m |
| Cash | $45.1m | $84.0m |
| Total debt | $1.1m | $0 |
| Debt to equity | 7.4% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 27 | 192 |
| Market value | $324m | $3.84bn |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 2 buys, 23 sales | 0 buys, 40 sales |